Next Article in Journal
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
Next Article in Special Issue
Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy
Previous Article in Journal
Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models
Previous Article in Special Issue
Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
Open AccessReview

Modelling Neuromuscular Diseases in the Age of Precision Medicine

Department of Paediatrics, University of Oxford, Oxford OX1 3QX, UK
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(4), 178; https://doi.org/10.3390/jpm10040178
Received: 23 September 2020 / Revised: 14 October 2020 / Accepted: 15 October 2020 / Published: 17 October 2020

Abstract

Advances in knowledge resulting from the sequencing of the human genome, coupled with technological developments and a deeper understanding of disease mechanisms of pathogenesis are paving the way for a growing role of precision medicine in the treatment of a number of human conditions. The goal of precision medicine is to identify and deliver effective therapeutic approaches based on patients’ genetic, environmental, and lifestyle factors. With the exception of cancer, neurological diseases provide the most promising opportunity to achieve treatment personalisation, mainly because of accelerated progress in gene discovery, deep clinical phenotyping, and biomarker availability. Developing reproducible, predictable and reliable disease models will be key to the rapid delivery of the anticipated benefits of precision medicine. Here we summarize the current state of the art of preclinical models for neuromuscular diseases, with particular focus on their use and limitations to predict safety and efficacy treatment outcomes in clinical trials.
Keywords: neuromuscular diseases; translational research; disease models; precision medicine neuromuscular diseases; translational research; disease models; precision medicine

1. Introduction

Neuromuscular diseases are a broad and heterogeneous group of conditions characterized by an impairment in one or more components of the motor unit, defined as the motor neuron and the muscle fibres it innervates. Whilst most are individually rare, collectively neuromuscular diseases are significantly prevalent, with a cumulative prevalence of approximately 100–200 cases per 100,000 individuals worldwide [1], accounting for a substantial proportion of population-wide health care costs [2]. Very few treatments currently exist to treat these diseases. Nevertheless, as research progressively disentangles their pathogenic mechanisms, many opportunities are finally starting to land in the clinic.
Precision medicine refers to a treatment approach wherein the most appropriate treatment for an individual is chosen based on their specific disease manifestation, alongside their genetic/epigenetic information and other features such as their microbiome, age, nutrition, and lifestyle. The clinical and genetic heterogeneity of neuromuscular diseases make them ideal candidates for personalized therapeutic approaches, with many individuals suffering from rare or ultrarare diseases that cannot be treated by conventional blanket approach treatment. One example is Duchenne muscular dystrophy (DMD), the most prevalent childhood-onset muscular dystrophy, where progressive muscle degeneration and weakness is caused by mutations in the DMD gene, leading to loss of dystrophin protein production [3]. The vast majority of DMD patients carry an exon deletion (~65%) or a duplication (~10%) of one or multiple exons and these mutations tend to manifest in regions of vulnerability between exons 2 and 20 and exons 45 and 55 [4,5,6]. In addition, small mutations (insertions, deletions, nonsense mutations and splice site mutations) account for the remaining ~25% mutations and occur throughout the length of the gene [4]. Excision of specific exons, or exon skipping, by use of antisense oligonucleotides (AON) to allow restoration of the disrupted reading frame and therefore production of a shortened but functional dystrophin protein, has surfaced as a promising therapy for DMD [7]. Therefore, diagnosis by genetic sequencing has become a crucial tool in determining eligibility for these treatments, as multiple AON products need to address the large series of mutations carried by DMD subjects.
While presenting new challenges for researchers, precision medicine is rapidly taking the lead in the pursuit of radically transforming health care. Choosing the appropriate disease model that recapitulates the complexity and heterogeneity of patients is therefore paramount to understand disease mechanisms and increase the chances of success of translating a treatment opportunity into a safe and effective marketed drug.
In this review, we aim to discuss the currently available tools used to model neuromuscular diseases and to evaluate their utility and applicability to personalized medical research and therapeutic development (Table 1).

2. Cellular Models

2.1. Myoblasts

Primary myoblasts (activated satellite cells) obtained from human subjects or animal models typically go through multiple rounds of cell division until reaching confluence in growth media, followed by iterations of cellular fusions to form multinuclear myotubes and eventually terminal differentiation [8]. Due to several inherent traits of human-derived muscle cells, including the slower growth rate as well as the flattened morphology, primary human myotubes typically exhibit poorer contractile activity than their mouse counterparts in response to electric stimulation [9]. Obtaining a substantial number of satellite cells from skeletal muscle biopsies of patients is markedly limited by the restricted proliferative capability of activated satellite cells in culture. In order to overcome this limitation, myogenic conversion of non-muscle primary cells, such as primary human and murine fibroblasts from skin, has been widely employed, mainly using transduction of MyoD gene (myogenic differentiation), a master regulator of skeletal muscle differentiation [10]. In order to increase proliferative capacity, transduction with both telomerase-expressing and cyclin-dependent kinase 4-expressing vectors has been used to produce immortalized human muscle stem-cell lines from patients with different muscle diseases such as DMD, limb-girdle muscular dystrophy type 2B, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular dystrophy and congenital muscular dystrophy [11]. These immortalized cultures have been extensively used both to study disease mechanism and to test treatment strategies.

2.2. Induced Pluripotent Stem Cells (iPSCs)

The development of induced pluripotent stem cell (iPSC) technology has brought a great paradigm shift in the field of precision medicine [12] and now they have a prominent role as a tool for disease modelling and drug screening. Moreover, they are highly expandable, are free from the ethical issues linked to the use of embryonic stem cells (ESCs), and their source of cells easily accessible.
Two major strategies have been recently developed to differentiate PSCs into satellite-like cells. The first involved overexpressing PAX7, the master transcription factor for satellite cells, in an inducible fashion [13]. After being generated from human embryonic stem cells and iPSCs, these cells showed capability for in vitro expansion and differentiation, as well as engraftment and myofibre formation in immunodeficient mice [13,14]. The second strategy involved the use of a small molecule, and consists of glycogen synthase kinase 3 beta (GSK3beta) inhibition, in order to activate the Wnt pathway, as well as treatment with fibroblast growth factor 2 (FGF2) in a minimal medium [15,16,17,18,19,20]. Alternative protocols have used bone morphogenic protein 4 (BMP4) inhibition to promote differentiation into the myogenic lineage [21,22,23], or Notch signalling inhibitor DAPT [24]. Purified by fluorescence-activated cell sorting (FACS) [15,19,24], partially purified, or unpurified [16,17,20,21,23], cell mixtures are then plated.
By generating an in vitro DMD model from patient-derived iPS cells, Shoji et al. noted excess Ca2+ influx in DMD myocytes when compared to control myocytes in response to stimulation via electricity. This was alleviated by restoring dystrophin expression via exon skipping, therefore establishing a model that recapitulates early DMD pathogenesis and is appropriate for assessing the efficacy of exon-skipping drugs by phenotypic assay [25]. IPSC models of several other neuromuscular diseases are currently available, including Miyoshi myopathy, a muscle disease caused by the mutation in dysferlin [26], Pompe disease, a paediatric disease caused by lysosomal glycogen accumulation in skeletal muscle that leads to muscle weakness [27], and myotonic dystrophy type 1, a multisystem disorder that affects skeletal and smooth muscle caused by a CTG trinucleotide repeat expansion in the non-coding region of the DMPK gene [28]. Overall, the introduction of iPSC technology has allowed scientists to model diseases directly from patients’ cells, this being a cornerstone for personalized medicine. However, if they are planned to be used for personalized cell therapy, several issues remain to be addressed, including alterations in the differentiation efficiency, line-to-line variability, and risk of tumorigenicity.

2.3. Urine-Derived Stem Cells

In addition to representing an ideal source of cells for generating iPSCs, with a reprogramming efficiency approximately 100-fold higher than that of fibroblasts [29], urine stem cells (USCs) can also be induced into myogenic lineage by direct MyoD1 reprogramming [30]. Muscle differentiation can be further enhanced by adding 3-deazaneplanocin A hydrochloride [31]. These cells carry pluripotency markers such as CD29, CD105, CD166, CD90, and CD13 [32], and are able to self-renew and differentiate into the mesodermal, endodermal and ectodermal lineage [33]. Direct reprogramming of these cells, which can be easily isolated by centrifugation method and standard cell culture, has been recently shown to efficiently and reproducibly establish human myogenic cells from patients with DMD and limb-girdle muscular dystrophy (LGMD) type 2 [30]. Upon further molecular characterisation, this cost-effective and efficient in vitro model system shows great potential for more efficient drug development and targeted therapies development for neuromuscular diseases.

2.4. Skeletal Muscle Organoids

As the use of human iPSCs for tissue engineering and disease modelling expands, iPSC-derived organoids are rapidly becoming a powerful tool for modelling human organogenesis, homeostasis, injury repair and disease aetiology [34]. These miniature 3D tissues are generated using a combination of signposted differentiation, morphogenetic processes, and the embryonic organogenesis mimicking intrinsically driven self-assembly of cells, resulting in architecture and function remarkably similar to their in vivo counterparts. By using natural or synthetic scaffolds to create the artificial tissue [35], these models account for the cell–cell and cell–extracellular matrix interactions as well as the mechanical and/or chemical cues [36,37]. The development of physiologically relevant 3D in vitro models holds great promise to provide more economic, scalable and reproducible means of testing drugs and therapies for successful clinical translation. Few studies have reported methods to engineer human skeletal muscle tissue [38,39,40,41,42,43]. Induced myogenic progenitor cells derived from multiple human iPSC lines have been shown to form functional skeletal muscle tissues and are able to survive, progressively vascularize, and maintain functionality when implanted into the hindlimb muscle or dorsal window chamber in immunocompromised mice [44]. Isogenic human iPSC-derived 3D artificial muscles from patients affected by DMD, limb-girdle type 2D, and lamin A/C (LMNA)-related muscular dystrophies have been recently generated, recapitulating several pathogenic hallmarks in these diseases and also showing potential for muscle engraftment [45]. These studies have indicated that generation of fully functional artificial muscles require the contribution from other cellular lineages, for example vascular cells and motor neurons [45,46,47,48,49]. The major challenges the field is currently facing are mainly related to improving organoids’ scalability as well as their complexity and maturity. Recent success in growing brain organoids using multiwell spinning bioreactors represents a significant step towards high-throughput drug screening via large-scale organoid generation [50]. These models resemble more closely foetal than adult tissue, therefore optimisation of protocols is essential before being able to advance these tissues into replacement therapy. Bearing in mind the speed at which the field has advanced over the past few years, the range of possible future applications of this platform in the study of human diseases and in regenerative medicine is expected to rapidly expand.

2.5. Muscle on Chip

Advancement in culturing models with mixed culture capabilities, together with the latest developments in 3D printing, microfluidics and microfabrication engineering, has led to the rapid expansion of organ-on-chip technologies. These platforms have recently attracted substantial interest due to their potential to be informative at multiple stages of the drug discovery process, while offering new ways to model disease states and perform mechanistic investigations in vitro. The critical and defining features of these platforms are the 3D structure, the possibility of integration of multiple cell types to reflect tissue physiology, and the presence of relevant biomechanical forces [51]. Organ on chips have been adapted for the human gut [52], heart [53], blood–brain barrier [54], and kidney [55]. Human primary myogenic cells have been engineered to form 3D myobundles, which respond to electrical stimuli and undergo dose-dependent hypertrophy or myopathy in response to pharmacological stimulation [40]. The decreased muscle regeneration capacity and weakness observed in DMD patients have been recapitulated in a human dystrophic skeletal muscle on a chip [56]. Using a 3D photo-patterning approach, other researchers have developed a skeletal muscle platform by confining a cell-laden gelatin network around two hydrogel pillars, which serve as anchoring sites for the cells, as the muscle tissues form and mature [57]. In other instances, neurons and rhabdomyocytes, both originating from mouse embryonic cells, have been differentiated in a 3D hydrogel culture, to effectively constitute a neuromuscular unit on a chip [58].
Tissue engineering requires a deep understanding of the functional interplay of cell types and the effect of the scaffold on cellular architecture, as well as careful characterising and validation of the model for the purpose of study. Additionally, due to safety concerns around the potential for unexpected toxic side effects, the biocompatibility of the materials to be used must be well profiled [51].
As iPSCs or adult stem cells taken from mass production of tissue organoids are increasingly employed as a source of cells for these platforms, organ on a chip represents an ideal tool for precision medicine.

2.6. Other

Sources in addition to the muscle-derived cells or reprogrammed cells can be employed to model muscle diseases. For example, melanocytes from DMD patients show the same morphological alterations as DMD muscle-derived cells [59]. Cultured melanocytes from skin biopsies have been shown to be a useful alternative to muscle biopsies for the mRNA-based molecular diagnosis of DMD [60]. Additionally, in the case of Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM), diseases caused by mutations in collagen VI genes [61], patients’ derived melanocytes recapitulated the mitochondrial dysfunction and ultrastructural alterations that are found in patient myoblasts [62].

3. Animal Models

3.1. Mouse Models

A large fraction of currently available therapies have been developed with the help of animal models, especially mice, mainly due to the high similarity in sequence homology and organ physiology to humans, as well as cost-effective husbandry. Additionally, the external environment in mice studies can be well controlled and monitored and studies using inbred mice allow resampling isogenic individuals, therefore minimising variability.
Nevertheless, many differences remain: mice are smaller in size, have a markedly reduced lifespan and an increased heart rate, just to name a few. Approximately 1% of human genes are not present in the mouse genome [63], while the differences in the promoter regions, non-coding sequences, and RNA splicing might be even more marked, accounting for species-specific disparities in gene expression that in some cases can affect disease phenotype [64,65]. Overall these considerations, together with the realisation that treatments in mice have frequently resulted in disappointing outcomes in clinical trials, have recently called into question the translational potential of findings in mouse models [66].
One way of making mouse models for studying human diseases more suitable is to follow approaches pioneered over 30 years ago, which comprise incorporating human DNA into the mouse genome (genetic humanisation) and/or engrafting human cells and tissue into mouse tissues (cellular humanisation) [67,68,69,70]. Genetic humanisation can be achieved through a variety of methods, most commonly by injection of plasmids or artificial chromosome vectors into the mouse zygotes. Transgenic models have substantially contributed to advancing the understanding of human disease and have helped develop treatment strategies. One notorious major breakthrough in biomedical research using transgenic mice carrying the human SMN2 gene led to the recent clinical approval of an AON, able to block an intronic splicing silencer in human SMN2 [71], increasing full-length SMN2 isoform expression, which compensates for the loss of SMN1 that causes spinal muscular atrophy [72,73,74,75].
However, some key features must be considered: the cDNA or genomic DNA used to generate the transgenic mice tend to integrate randomly in multiple copies and thus overexpress the protein of interest. Overexpression of wild-type proteins may give a dose-dependent phenotype not related to the disease mutation, like in the case of the androgen receptor [76], and RNA binding proteins, such as TAR DNA-binding protein 43 [77]. The rise of genome engineering technology has revolutionized the field of molecular biology by allowing the generation of physiological, humanized knock-in mice models by precise editing [78,79]. Most DMD preclinical studies have been carried out in the mdx mouse that carries a nonsense point mutation in DMD exon 23 [80], which is only one out of the thousands of possible variations in this gene present in DMD patients. Despite a lack of dystrophin expression, these mice do not exhibit dilated cardiomyopathy or a shortened lifespan. To improve upon this model, a number of double knock-out mouse models have been created, such as mice deficient in both dystrophin and its homolog utrophin, which show decreased cardiac function and survival [81]. In recent years by using clustered regularly interspaced short palindromic repeat (CRISPR)-based editing, many new DMD mouse models carrying deletions, frameshifting mutations, a point mutation, and a mutant version of the human DMD gene have been generated [82,83,84,85,86,87,88], making testing of exon skipping strategies targeting different parts of the DMD transcript possible. It is worth considering that recent studies to assess the effects of disease-causing mutations or environmental stimuli in different mouse strains found a strong influence of the genetic background on phenotypic responses [89], highlighting the importance of genetic diversity of animal models in biomedical research.
It is becoming more and more evident that choosing the right model is critical. Depending on the specific research question, often combining different strains is the most appropriate way to minimize the risks of a lack of reproducibility of translational research. Despite the obvious differences between mice and humans, genetic mouse models have allowed us to look at the effects of a mutation at a system level. Combining genetic engineering, which has made genetic modifications of endogenous targets possible, with the use of genetic with cellular humanisation, we now have powerful tools to study human pathophysiology in vivo, in cell-autonomous and non-cell-autonomous contexts [90], as well as excellent preclinical models to identify and test the pharmacodynamic and pharmacokinetic properties of a treatment strategy, from gene therapy to small-molecule and cell replacement [91]. Overall, these considerations further support the use of ‘mouse precision medicine’ as a better prototype for future mouse studies.

3.2. Drosophila Melanogaster

Drosophila melanogaster can serve as a useful model of human neuromuscular disease, since flies have a neural circuitry, albeit much simpler than in humans, as well as multinucleated muscle cells and neuromuscular junctions (NMJ). The mechanisms of synaptic transmission seen at the NMJ in humans are conserved in Drosophila, with a key difference being that Drosophila uses glutamate, not acetylcholine, as the neurotransmitter. The ability to genetically manipulate Drosophila is useful when trying to better understand how certain myopathies occur. Moreover, their short life span and large progeny make flies a good system for carrying out large-scale genetic screens. Drosophila has helped us understand more about the NMJ, and in particular, the role that the dystrophin–glycoprotein complex plays (DGC). Like in mammals, the Drosophila gene of dystrophin also encodes multiple isoforms, which contain highly conserved domains and are mainly expressed in the muscle and the nervous system [92,93,94]. Studies into DGC function at the NMJ of Drosophila have shown that it plays an important role in the retrograde control of neurotransmitter release, neuronal migration and muscle stability and thus may help explain how neuromuscular pathology can occur. Removal of a dystrophin isoform (DLP2) in Drosophila, which is normally located at the post-synapse, has been shown to lead to an increase in presynaptic neurotransmitter release, causing increased muscle depolarisation, thus indicating a role of dystrophin in regulating presynaptic neurotransmitter release [95]. Previous work has shown that by studying sensory neurons (photoreceptor cells) in Drosophila [96], a lot can be learnt about axon guidance and target recognition. Perturbation of dystrophin and dystroglycan in photoreceptor cells led to disrupted axon guidance, similar to neuronal defects seen in human muscular dystrophy patients. Drosophila not only aids us in understanding the role that certain proteins play at the synapse of the NMJ, but also serves as a good model for studying age-dependent progression of muscular dystrophy. The reduction in levels of expression of dystrophin isoforms in Drosophila using RNAi led to muscle degeneration in larval and adult flies [95], thus potentially providing a useful model to help us understand Duchenne muscular dystrophy pathogenesis in humans.

3.3. Zebrafish

The zebrafish (Danio rerio) has become a useful organism for studying neuromuscular genetic disorders [97]. Comparison to the human reference genome has shown that approximately 70% of human genes have at least one zebrafish orthologue [98], and dozens of mutant zebrafish lines have already been generated to model the most common human myopathies [99,100,101]. As vertebrates, they possess desirable attributes, including small size, rapid development, and genetic tractability [97]. Zebrafish embryos are transparent, develop externally and can be easily genetically manipulated [102], making this model ideal for phenotypic high-throughput screening platform to investigate drug efficacy in a whole-organism context. The most commonly adopted screening criteria for assessing neuromuscular phenotype are spontaneous coiling, ability to hatch on time, swimming behaviour, and birefringence assay [103]. Compared to target-based drug discovery, a phenotype-driven approach offers several key advantages [104], such as rapid identification of compounds that have poor bioavailability, exhibit toxicity or off-target effects. By screening small-molecule libraries in the dystrophin-null zebrafish (sapje model), aminophylline, a non-selective phosphodiesterase inhibitor, was found to improve survival rate in animals, restore normal muscle structure and up-regulate the cAMP-dependent PKA pathway without affecting dystrophin expression [105]. In the sapje model, the mitochondrial defects present in DMD patients were recapitulated, making it an optimal model for the disease, and it was used to assess the effect of the cyclophilin inhibitor alisporivir treatment in vivo, resulting in an improvement in the morphology of mitochondria and myofibrils, and in mitochondrial respiration [106]. A zebrafish model showing severe myopathy has also been generated for UCMD via a deletion in the col6a1 gene through the injection of an antisense morpholino [107]. Here, defects in the mitochondria permeability transition pore (mPTP) were corrected with the cyclophilin inhibitor NIM811 treatment [108]. In another study, the zebrafish model was used to test mitochondrial respiratory capacity after treatment with stable analogues of mPTP inhibitors [109]. Additionally, the zebrafish model has also provided insight into functional aspects of disease pathogenesis for several muscle conditions: for example, studies in zebrafish relatively relaxed (ryr) mutant, a model of RYR1-related myopathies [110], have contributed to identifying oxidative stress as an important disease mechanism in RYR1-related myopathies [111].

3.4. Caenorhabditis Elegans

With 40% of human disease genes having a nematode ortholog [112], and a fully sequenced genome [113], C. elegans is a valuable model to investigate several human physiological and pathological mechanisms. Studies of sarcomere maintenance and function in striated muscle led to the first identification of many conserved proteins, including twitchin, unc-89 (obscurin), unc-112 (kindlin), unc-45 (myosin chaperone) and unc-78 (AIP1) [114]. Using a large-scale screens in a C. elegans model of muscular dystrophy, carrying mutations in the dys-1 and the hlh-1 genes, which are respectively the homolog for the mammalian dystrophin and MyoD gene [115], compounds such as prednisone and serotonin have been shown to be effective in reducing muscle degeneration [116,117]. The obvious advantages of using this scalable and high-throughput model are counterbalanced by the limited phenotypic analyses, such as counting the number of times a worm bends in a C-shaped fashion in liquid in one minute, although new automated methods of quantifying muscle contraction and relaxation kinetics are emerging [118].

4. Computational Models

In silico models are becoming an increasingly useful tool for investigating muscle function and in helping us to understand which key players cause muscle pathology. These models integrate published experimental data, thus allowing us to encompass the many variables linked to pathology in a single model, enabling the study of multifaceted diseases. In doing these studies, one may understand better the underlying interactions between different disease mechanisms that lead to pathology, which may prove harder to do in live experiments. Over the last twenty years, big steps have been made in the computational modelling of muscle. A recent development has been the creation of agent-based models (ABMs), which allow us to assess what roles different biological agents play in muscle pathology, both at cellular and systems levels. For example, the use of ABMs for DMD has indicated a link between low satellite stem cell counts and impaired muscle regeneration symptom [119]. ABMs can also be used to predict the outcomes of given scenarios based on the rules derived from the literature, as well as having certain parameters that cannot be measured experimentally. This system can even add software agents that mimic certain biological cells into the simulation, with the aim of helping us to better understand their cellular interactions. This has been carried out in studies showing that fibroblasts can affect a muscle’s susceptibility to disuse-induced atrophy [120].
However, these models do have their limitations: the simulated model is not a full replicate of the muscle cell and its microenvironment, as it only accounts for the contribution of known variables, which renders this model system not fully translatable to the in vivo situation.

5. Conclusions

The increasing availability of genetic and phenotypic information on patients with neuromuscular diseases, coupled with the unprecedented opportunity to manipulate eukaryotic genomes to generate disease models to study these diseases, has the potential to accelerate the translation of new therapeutic opportunities from preclinical settings into medical practice. Among the models available to researchers, 3D cultures and muscle on chips are best suited for precision medicine applications, due to their structural complexity and opportunity for genetic and environmental manipulation. However, as it becomes increasingly evident that we need to abandon the concept of ‘one drug fits all’, modelling every disease-associated variant for preclinical applications is likely to be unattainable and in many cases unnecessary. Achieving model precision is critical in translational research as long as it provides predictive validity, which is the ultimate goal of preclinical work, and may further be enhanced by using multiple models to capture the spectrum of mechanisms and testing therapies in diverse genetic backgrounds that more closely reflect the human population as a whole. This may be particularly true in complex diseases, where multiple risk loci concur to the development of a specific condition or to the treatment response.

Author Contributions

Literature review, writing and original draft preparation, A.A.S.; writing, review and editing, A.A.S., R.E., T.G., and C.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Deenen, J.C.; Horlings, C.G.; Verschuuren, J.J.; Verbeek, A.L.; van Engelen, B.G. The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. J. Neuromuscul. Dis. 2015, 2, 73–85. [Google Scholar] [CrossRef] [PubMed]
  2. Olesen, J.; Gustavsson, A.; Svensson, M.; Wittchen, H.U.; Jonsson, B.; CDBE2010 Study Group; European Brain Council. The economic cost of brain disorders in Europe. Eur. J. Neurol. 2012, 19, 155–162. [Google Scholar] [CrossRef]
  3. Blake, D.J.; Weir, A.; Newey, S.E.; Davies, K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002, 82, 291–329. [Google Scholar] [CrossRef] [PubMed]
  4. Aartsma-Rus, A.; Van Deutekom, J.C.; Fokkema, I.F.; Van Ommen, G.J.; Den Dunnen, J.T. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006, 34, 135–144. [Google Scholar] [CrossRef] [PubMed]
  5. Beggs, A.H.; Koenig, M.; Boyce, F.M.; Kunkel, L.M. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum. Genet. 1990, 86, 45–48. [Google Scholar] [CrossRef] [PubMed]
  6. Liechti-Gallati, S.; Koenig, M.; Kunkel, L.M.; Frey, D.; Boltshauser, E.; Schneider, V.; Braga, S.; Moser, H. Molecular deletion patterns in Duchenne and Becker type muscular dystrophy. Hum. Genet. 1989, 81, 343–348. [Google Scholar] [CrossRef]
  7. Dzierlega, K.; Yokota, T. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther. 2020, 27, 407–416. [Google Scholar] [CrossRef]
  8. Koide, M.; Hagiwara, Y.; Tsuchiya, M.; Kanzaki, M.; Hatakeyama, H.; Tanaka, Y.; Minowa, T.; Takemura, T.; Ando, A.; Sekiguchi, T.; et al. Retained Myogenic Potency of Human Satellite Cells from Torn Rotator Cuff Muscles Despite Fatty Infiltration. Tohoku J. Exp. Med. 2018, 244, 15–24. [Google Scholar] [CrossRef]
  9. Chen, W.; Nyasha, M.R.; Koide, M.; Tsuchiya, M.; Suzuki, N.; Hagiwara, Y.; Aoki, M.; Kanzaki, M. In vitro exercise model using contractile human and mouse hybrid myotubes. Sci. Rep. 2019, 9, 11914. [Google Scholar] [CrossRef]
  10. Lattanzi, L.; Salvatori, G.; Coletta, M.; Sonnino, C.; Cusella De Angelis, M.G.; Gioglio, L.; Murry, C.E.; Kelly, R.; Ferrari, G.; Molinaro, M.; et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J. Clin. Investig. 1998, 101, 2119–2128. [Google Scholar] [CrossRef]
  11. Mamchaoui, K.; Trollet, C.; Bigot, A.; Negroni, E.; Chaouch, S.; Wolff, A.; Kandalla, P.K.; Marie, S.; Di Santo, J.; St Guily, J.L.; et al. Immortalized pathological human myoblasts: Towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 2011, 1, 34. [Google Scholar] [CrossRef]
  12. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663–676. [Google Scholar] [CrossRef] [PubMed]
  13. Darabi, R.; Arpke, R.W.; Irion, S.; Dimos, J.T.; Grskovic, M.; Kyba, M.; Perlingeiro, R.C. Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 2012, 10, 610–619. [Google Scholar] [CrossRef] [PubMed]
  14. Magli, A.; Incitti, T.; Kiley, J.; Swanson, S.A.; Darabi, R.; Rinaldi, F.; Selvaraj, S.; Yamamoto, A.; Tolar, J.; Yuan, C.; et al. PAX7 Targets, CD54, Integrin alpha9beta1, and SDC2, Allow Isolation of Human ESC/iPSC-Derived Myogenic Progenitors. Cell Rep. 2017, 19, 2867–2877. [Google Scholar] [CrossRef]
  15. Borchin, B.; Chen, J.; Barberi, T. Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells. Stem Cell Rep. 2013, 1, 620–631. [Google Scholar] [CrossRef] [PubMed]
  16. Caron, L.; Kher, D.; Lee, K.L.; McKernan, R.; Dumevska, B.; Hidalgo, A.; Li, J.; Yang, H.; Main, H.; Ferri, G.; et al. A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles. Stem Cells Transl. Med. 2016, 5, 1145–1161. [Google Scholar] [CrossRef] [PubMed]
  17. Shelton, M.; Metz, J.; Liu, J.; Carpenedo, R.L.; Demers, S.P.; Stanford, W.L.; Skerjanc, I.S. Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells. Stem Cell Rep. 2014, 3, 516–529. [Google Scholar] [CrossRef]
  18. Shelton, M.; Kocharyan, A.; Liu, J.; Skerjanc, I.S.; Stanford, W.L. Robust generation and expansion of skeletal muscle progenitors and myocytes from human pluripotent stem cells. Methods 2016, 101, 73–84. [Google Scholar] [CrossRef]
  19. van der Wal, E.; Bergsma, A.J.; van Gestel, T.J.M.; In’t Groen, S.L.M.; Zaehres, H.; Arauzo-Bravo, M.J.; Scholer, H.R.; van der Ploeg, A.T.; Pijnappel, W. GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells. Mol. Ther. Nucleic Acids 2017, 7, 101–115. [Google Scholar] [CrossRef]
  20. Xu, C.; Tabebordbar, M.; Iovino, S.; Ciarlo, C.; Liu, J.; Castiglioni, A.; Price, E.; Liu, M.; Barton, E.R.; Kahn, C.R.; et al. A zebrafish embryo culture system defines factors that promote vertebrate myogenesis across species. Cell 2013, 155, 909–921. [Google Scholar] [CrossRef]
  21. Chal, J.; Oginuma, M.; Al Tanoury, Z.; Gobert, B.; Sumara, O.; Hick, A.; Bousson, F.; Zidouni, Y.; Mursch, C.; Moncuquet, P.; et al. Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy. Nat. Biotechnol. 2015, 33, 962–969. [Google Scholar] [CrossRef]
  22. Chal, J.; Al Tanoury, Z.; Hestin, M.; Gobert, B.; Aivio, S.; Hick, A.; Cherrier, T.; Nesmith, A.P.; Parker, K.K.; Pourquie, O. Generation of human muscle fibers and satellite-like cells from human pluripotent stem cells in vitro. Nat. Protoc. 2016, 11, 1833–1850. [Google Scholar] [CrossRef] [PubMed]
  23. Swartz, E.W.; Baek, J.; Pribadi, M.; Wojta, K.J.; Almeida, S.; Karydas, A.; Gao, F.B.; Miller, B.L.; Coppola, G. A Novel Protocol for Directed Differentiation of C9orf72-Associated Human Induced Pluripotent Stem Cells Into Contractile Skeletal Myotubes. Stem Cells Transl. Med. 2016, 5, 1461–1472. [Google Scholar] [CrossRef]
  24. Choi, I.Y.; Lim, H.; Estrellas, K.; Mula, J.; Cohen, T.V.; Zhang, Y.; Donnelly, C.J.; Richard, J.P.; Kim, Y.J.; Kim, H.; et al. Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Rep. 2016, 15, 2301–2312. [Google Scholar] [CrossRef]
  25. Shoji, E.; Sakurai, H.; Nishino, T.; Nakahata, T.; Heike, T.; Awaya, T.; Fujii, N.; Manabe, Y.; Matsuo, M.; Sehara-Fujisawa, A. Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci. Rep. 2015, 5, 12831. [Google Scholar] [CrossRef] [PubMed]
  26. Liu, J.; Aoki, M.; Illa, I.; Wu, C.; Fardeau, M.; Angelini, C.; Serrano, C.; Urtizberea, J.A.; Hentati, F.; Hamida, M.B.; et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 1998, 20, 31–36. [Google Scholar] [CrossRef] [PubMed]
  27. Yoshida, T.; Awaya, T.; Jonouchi, T.; Kimura, R.; Kimura, S.; Era, T.; Heike, T.; Sakurai, H. A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells. Sci. Rep. 2017, 7, 13473. [Google Scholar] [CrossRef]
  28. Ueki, J.; Nakamori, M.; Nakamura, M.; Nishikawa, M.; Yoshida, Y.; Tanaka, A.; Morizane, A.; Kamon, M.; Araki, T.; Takahashi, M.P.; et al. Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability. Sci. Rep. 2017, 7, 42522. [Google Scholar] [CrossRef]
  29. Ousterout, D.G.; Kabadi, A.M.; Thakore, P.I.; Majoros, W.H.; Reddy, T.E.; Gersbach, C.A. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 2015, 6, 6244. [Google Scholar] [CrossRef]
  30. Kim, E.Y.; Page, P.; Dellefave-Castillo, L.M.; McNally, E.M.; Wyatt, E.J. Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease. Skelet Muscle 2016, 6, 32. [Google Scholar] [CrossRef]
  31. Takizawa, H.; Hara, Y.; Mizobe, Y.; Ohno, T.; Suzuki, S.; Inoue, K.; Takeshita, E.; Shimizu-Motohashi, Y.; Ishiyama, A.; Hoshino, M.; et al. Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride. Sci. Rep. 2019, 9, 3807. [Google Scholar] [CrossRef]
  32. He, W.; Zhu, W.; Cao, Q.; Shen, Y.; Zhou, Q.; Yu, P.; Liu, X.; Ma, J.; Li, Y.; Hong, K. Generation of Mesenchymal-Like Stem Cells From Urine in Pediatric Patients. Transplant. Proc. 2016, 48, 2181–2185. [Google Scholar] [CrossRef]
  33. Zhang, Y.; McNeill, E.; Tian, H.; Soker, S.; Andersson, K.E.; Yoo, J.J.; Atala, A. Urine derived cells are a potential source for urological tissue reconstruction. J. Urol. 2008, 180, 2226–2233. [Google Scholar] [CrossRef] [PubMed]
  34. Passier, R.; Orlova, V.; Mummery, C. Complex Tissue and Disease Modeling using hiPSCs. Cell Stem Cell 2016, 18, 309–321. [Google Scholar] [CrossRef]
  35. Langer, R.; Vacanti, J.P. Tissue engineering. Science 1993, 260, 920–926. [Google Scholar] [CrossRef]
  36. Discher, D.E.; Janmey, P.; Wang, Y.L. Tissue cells feel and respond to the stiffness of their substrate. Science 2005, 310, 1139–1143. [Google Scholar] [CrossRef]
  37. Schmeichel, K.L.; Bissell, M.J. Modeling tissue-specific signaling and organ function in three dimensions. J. Cell Sci. 2003, 116, 2377–2388. [Google Scholar] [CrossRef] [PubMed]
  38. Chiron, S.; Tomczak, C.; Duperray, A.; Laine, J.; Bonne, G.; Eder, A.; Hansen, A.; Eschenhagen, T.; Verdier, C.; Coirault, C. Complex interactions between human myoblasts and the surrounding 3D fibrin-based matrix. PLoS ONE 2012, 7, e36173. [Google Scholar] [CrossRef]
  39. Fuoco, C.; Rizzi, R.; Biondo, A.; Longa, E.; Mascaro, A.; Shapira-Schweitzer, K.; Kossovar, O.; Benedetti, S.; Salvatori, M.L.; Santoleri, S.; et al. In vivo generation of a mature and functional artificial skeletal muscle. EMBO Mol. Med. 2015, 7, 411–422. [Google Scholar] [CrossRef] [PubMed]
  40. Madden, L.; Juhas, M.; Kraus, W.E.; Truskey, G.A.; Bursac, N. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. eLife 2015, 4, e04885. [Google Scholar] [CrossRef]
  41. Powell, C.; Shansky, J.; Del Tatto, M.; Forman, D.E.; Hennessey, J.; Sullivan, K.; Zielinski, B.A.; Vandenburgh, H.H. Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum. Gene Ther. 1999, 10, 565–577. [Google Scholar] [CrossRef] [PubMed]
  42. Quarta, M.; Cromie, M.; Chacon, R.; Blonigan, J.; Garcia, V.; Akimenko, I.; Hamer, M.; Paine, P.; Stok, M.; Shrager, J.B.; et al. Bioengineered constructs combined with exercise enhance stem cell-mediated treatment of volumetric muscle loss. Nat. Commun. 2017, 8, 15613. [Google Scholar] [CrossRef]
  43. Tchao, J.; Kim, J.J.; Lin, B.; Salama, G.; Lo, C.W.; Yang, L.; Tobita, K. Engineered Human Muscle Tissue from Skeletal Muscle Derived Stem Cells and Induced Pluripotent Stem Cell Derived Cardiac Cells. Int. J. Tissue Eng. 2013, 2013, 198762. [Google Scholar] [CrossRef] [PubMed]
  44. Rao, L.; Qian, Y.; Khodabukus, A.; Ribar, T.; Bursac, N. Engineering human pluripotent stem cells into a functional skeletal muscle tissue. Nat. Commun. 2018, 9, 126. [Google Scholar] [CrossRef] [PubMed]
  45. Maffioletti, S.M.; Sarcar, S.; Henderson, A.B.H.; Mannhardt, I.; Pinton, L.; Moyle, L.A.; Steele-Stallard, H.; Cappellari, O.; Wells, K.E.; Ferrari, G.; et al. Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering. Cell Rep. 2018, 23, 899–908. [Google Scholar] [CrossRef] [PubMed]
  46. Christov, C.; Chretien, F.; Abou-Khalil, R.; Bassez, G.; Vallet, G.; Authier, F.J.; Bassaglia, Y.; Shinin, V.; Tajbakhsh, S.; Chazaud, B.; et al. Muscle satellite cells and endothelial cells: Close neighbors and privileged partners. Mol. Biol. Cell 2007, 18, 1397–1409. [Google Scholar] [CrossRef] [PubMed]
  47. Ecob-Prince, M.S.; Jenkison, M.; Butler-Browne, G.S.; Whalen, R.G. Neonatal and adult myosin heavy chain isoforms in a nerve-muscle culture system. J. Cell Biol. 1986, 103, 995–1005. [Google Scholar] [CrossRef]
  48. Kostallari, E.; Baba-Amer, Y.; Alonso-Martin, S.; Ngoh, P.; Relaix, F.; Lafuste, P.; Gherardi, R.K. Pericytes in the myovascular niche promote post-natal myofiber growth and satellite cell quiescence. Development 2015, 142, 1242–1253. [Google Scholar] [CrossRef]
  49. Perry, L.; Flugelman, M.Y.; Levenberg, S. Elderly Patient-Derived Endothelial Cells for Vascularization of Engineered Muscle. Mol. Ther. 2017, 25, 935–948. [Google Scholar] [CrossRef]
  50. Qian, X.; Nguyen, H.N.; Song, M.M.; Hadiono, C.; Ogden, S.C.; Hammack, C.; Yao, B.; Hamersky, G.R.; Jacob, F.; Zhong, C.; et al. Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell 2016, 165, 1238–1254. [Google Scholar] [CrossRef]
  51. Low, L.A.; Mummery, C.; Berridge, B.R.; Austin, C.P.; Tagle, D.A. Organs-on-chips: Into the next decade. Nat. Rev. Drug Discov. 2020. [Google Scholar] [CrossRef] [PubMed]
  52. Kim, H.J.; Huh, D.; Hamilton, G.; Ingber, D.E. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 2012, 12, 2165–2174. [Google Scholar] [CrossRef] [PubMed]
  53. Maoz, B.M.; Herland, A.; Henry, O.Y.F.; Leineweber, W.D.; Yadid, M.; Doyle, J.; Mannix, R.; Kujala, V.J.; FitzGerald, E.A.; Parker, K.K.; et al. Organs-on-Chips with combined multi-electrode array and transepithelial electrical resistance measurement capabilities. Lab Chip 2017, 17, 2294–2302. [Google Scholar] [CrossRef]
  54. Herland, A.; van der Meer, A.D.; FitzGerald, E.A.; Park, T.E.; Sleeboom, J.J.; Ingber, D.E. Distinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a Chip. PLoS ONE 2016, 11, e0150360. [Google Scholar] [CrossRef]
  55. Musah, S.; Mammoto, A.; Ferrante, T.C.; Jeanty, S.S.F.; Hirano-Kobayashi, M.; Mammoto, T.; Roberts, K.; Chung, S.; Novak, R.; Ingram, M.; et al. Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip. Nat. Biomed. Eng. 2017, 1. [Google Scholar] [CrossRef] [PubMed]
  56. Nesmith, A.P.; Wagner, M.A.; Pasqualini, F.S.; O’Connor, B.B.; Pincus, M.J.; August, P.R.; Parker, K.K. A human in vitro model of Duchenne muscular dystrophy muscle formation and contractility. J. Cell Biol. 2016, 215, 47–56. [Google Scholar] [CrossRef] [PubMed]
  57. Agrawal, G.; Aung, A.; Varghese, S. Skeletal muscle-on-a-chip: An in vitro model to evaluate tissue formation and injury. Lab Chip 2017, 17, 3447–3461. [Google Scholar] [CrossRef]
  58. Uzel, S.G.; Platt, R.J.; Subramanian, V.; Pearl, T.M.; Rowlands, C.J.; Chan, V.; Boyer, L.A.; So, P.T.; Kamm, R.D. Microfluidic device for the formation of optically excitable, three-dimensional, compartmentalized motor units. Sci. Adv. 2016, 2, e1501429. [Google Scholar] [CrossRef]
  59. Pellegrini, C.; Zulian, A.; Gualandi, F.; Manzati, E.; Merlini, L.; Michelini, M.E.; Benassi, L.; Marmiroli, S.; Ferlini, A.; Sabatelli, P.; et al. Melanocytes--A novel tool to study mitochondrial dysfunction in Duchenne muscular dystrophy. J. Cell Physiol. 2013, 228, 1323–1331. [Google Scholar] [CrossRef]
  60. Tyers, L.; Davids, L.M.; Wilmshurst, J.M.; Esterhuizen, A.I. Skin cells for use in an alternate diagnostic method for Duchenne muscular dystrophy. Neuromuscul. Disord. 2018, 28, 553–563. [Google Scholar] [CrossRef]
  61. Lampe, A.K.; Bushby, K.M. Collagen VI related muscle disorders. J. Med. Genet. 2005, 42, 673–685. [Google Scholar] [CrossRef] [PubMed]
  62. Zulian, A.; Tagliavini, F.; Rizzo, E.; Pellegrini, C.; Sardone, F.; Zini, N.; Maraldi, N.M.; Santi, S.; Faldini, C.; Merlini, L.; et al. Melanocytes from Patients Affected by Ullrich Congenital Muscular Dystrophy and Bethlem Myopathy have Dysfunctional Mitochondria That Can be Rescued with Cyclophilin Inhibitors. Front. Aging Neurosci. 2014, 6, 324. [Google Scholar] [CrossRef]
  63. Waterston, R.H.; Lindblad-Toh, K.; Birney, E.; Rogers, J.; Abril, J.F.; Agarwal, P.; Agarwala, R.; Ainscough, R.; Alexandersson, M.; An, P.; et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002, 420, 520–562. [Google Scholar] [CrossRef] [PubMed]
  64. Lee, Y.; Rio, D.C. Mechanisms and Regulation of Alternative Pre-mRNA Splicing. Annu. Rev. Biochem. 2015, 84, 291–323. [Google Scholar] [CrossRef]
  65. Deveson, I.W.; Brunck, M.E.; Blackburn, J.; Tseng, E.; Hon, T.; Clark, T.A.; Clark, M.B.; Crawford, J.; Dinger, M.E.; Nielsen, L.K.; et al. Universal Alternative Splicing of Noncoding Exons. Cell Syst. 2018, 6, 245–255.e5. [Google Scholar] [CrossRef]
  66. Seok, J.; Warren, H.S.; Cuenca, A.G.; Mindrinos, M.N.; Baker, H.V.; Xu, W.; Richards, D.R.; McDonald-Smith, G.P.; Gao, H.; Hennessy, L.; et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA 2013, 110, 3507–3512. [Google Scholar] [CrossRef]
  67. Brundin, P.; Nilsson, O.G.; Strecker, R.E.; Lindvall, O.; Astedt, B.; Bjorklund, A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson’s disease. Exp. Brain Res. 1986, 65, 235–240. [Google Scholar] [CrossRef]
  68. Gordon, J.W.; Ruddle, F.H. Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 1981, 214, 1244–1246. [Google Scholar] [CrossRef]
  69. Gumpel, M.; Lachapelle, F.; Gansmuller, A.; Baulac, M.; Baron van Evercooren, A.; Baumann, N. Transplantation of human embryonic oligodendrocytes into shiverer brain. Ann. N. Y. Acad. Sci. 1987, 495, 71–85. [Google Scholar] [CrossRef] [PubMed]
  70. Stromberg, I.; Bygdeman, M.; Goldstein, M.; Seiger, A.; Olson, L. Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: Evidence for functional reinnervation. Neurosci. Lett. 1986, 71, 271–276. [Google Scholar] [CrossRef]
  71. Schoch, K.M.; Miller, T.M. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron 2017, 94, 1056–1070. [Google Scholar] [CrossRef] [PubMed]
  72. Hua, Y.; Sahashi, K.; Rigo, F.; Hung, G.; Horev, G.; Bennett, C.F.; Krainer, A.R. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478, 123–126. [Google Scholar] [CrossRef]
  73. Passini, M.A.; Bu, J.; Richards, A.M.; Kinnecom, C.; Sardi, S.P.; Stanek, L.M.; Hua, Y.; Rigo, F.; Matson, J.; Hung, G.; et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011, 3, 72ra18. [Google Scholar] [CrossRef] [PubMed]
  74. Porensky, P.N.; Mitrpant, C.; McGovern, V.L.; Bevan, A.K.; Foust, K.D.; Kaspar, B.K.; Wilton, S.D.; Burghes, A.H. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 2012, 21, 1625–1638. [Google Scholar] [CrossRef] [PubMed]
  75. Williams, J.H.; Schray, R.C.; Patterson, C.A.; Ayitey, S.O.; Tallent, M.K.; Lutz, G.J. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 2009, 29, 7633–7638. [Google Scholar] [CrossRef] [PubMed]
  76. Coome, L.A.; Swift-Gallant, A.; Ramzan, F.; Melhuish Beaupre, L.; Brkic, T.; Monks, D.A. Neural androgen receptor overexpression affects cell number in the spinal nucleus of the bulbocavernosus. J. Neuroendocrinol. 2017, 29, 12515. [Google Scholar] [CrossRef] [PubMed]
  77. De Giorgio, F.; Maduro, C.; Fisher, E.M.C.; Acevedo-Arozena, A. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis. Model. Mech. 2019, 12. [Google Scholar] [CrossRef]
  78. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A.; et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [Google Scholar] [CrossRef]
  79. Mali, P.; Esvelt, K.M.; Church, G.M. Cas9 as a versatile tool for engineering biology. Nat. Methods 2013, 10, 957–963. [Google Scholar] [CrossRef]
  80. Sicinski, P.; Geng, Y.; Ryder-Cook, A.S.; Barnard, E.A.; Darlison, M.G.; Barnard, P.J. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 1989, 244, 1578–1580. [Google Scholar] [CrossRef]
  81. Deconinck, A.E.; Rafael, J.A.; Skinner, J.A.; Brown, S.C.; Potter, A.C.; Metzinger, L.; Watt, D.J.; Dickson, J.G.; Tinsley, J.M.; Davies, K.E. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997, 90, 717–727. [Google Scholar] [CrossRef]
  82. Kim, K.; Ryu, S.M.; Kim, S.T.; Baek, G.; Kim, D.; Lim, K.; Chung, E.; Kim, S.; Kim, J.S. Highly efficient RNA-guided base editing in mouse embryos. Nat. Biotechnol. 2017, 35, 435–437. [Google Scholar] [CrossRef] [PubMed]
  83. Amoasii, L.; Long, C.; Li, H.; Mireault, A.A.; Shelton, J.M.; Sanchez-Ortiz, E.; McAnally, J.R.; Bhattacharyya, S.; Schmidt, F.; Grimm, D.; et al. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci. Transl. Med. 2017, 9, 418. [Google Scholar] [CrossRef] [PubMed]
  84. Young, C.S.; Mokhonova, E.; Quinonez, M.; Pyle, A.D.; Spencer, M.J. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy. J. Neuromuscul. Dis. 2017, 4, 139–145. [Google Scholar] [CrossRef] [PubMed]
  85. Koo, T.; Lu-Nguyen, N.B.; Malerba, A.; Kim, E.; Kim, D.; Cappellari, O.; Cho, H.Y.; Dickson, G.; Popplewell, L.; Kim, J.S. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9. Mol. Ther. 2018, 26, 1529–1538. [Google Scholar] [CrossRef]
  86. Min, Y.L.; Li, H.; Rodriguez-Caycedo, C.; Mireault, A.A.; Huang, J.; Shelton, J.M.; McAnally, J.R.; Amoasii, L.; Mammen, P.P.A.; Bassel-Duby, R.; et al. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 2019, 5, eaav4324. [Google Scholar] [CrossRef] [PubMed]
  87. Egorova, T.V.; Zotova, E.D.; Reshetov, D.A.; Polikarpova, A.V.; Vassilieva, S.G.; Vlodavets, D.V.; Gavrilov, A.A.; Ulianov, S.V.; Buchman, V.L.; Deykin, A.V. CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. Dis. Model. Mech. 2019, 12. [Google Scholar] [CrossRef]
  88. Amoasii, L.; Li, H.; Zhang, Y.; Min, Y.L.; Sanchez-Ortiz, E.; Shelton, J.M.; Long, C.; Mireault, A.A.; Bhattacharyya, S.; McAnally, J.R.; et al. In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse. Nat. Commun. 2019, 10, 4537. [Google Scholar] [CrossRef]
  89. Sittig, L.J.; Carbonetto, P.; Engel, K.A.; Krauss, K.S.; Barrios-Camacho, C.M.; Palmer, A.A. Genetic Background Limits Generalizability of Genotype-Phenotype Relationships. Neuron 2016, 91, 1253–1259. [Google Scholar] [CrossRef] [PubMed]
  90. Espuny-Camacho, I.; Arranz, A.M.; Fiers, M.; Snellinx, A.; Ando, K.; Munck, S.; Bonnefont, J.; Lambot, L.; Corthout, N.; Omodho, L.; et al. Hallmarks of Alzheimer’s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain. Neuron 2017, 93, 1066–1081. [Google Scholar] [CrossRef] [PubMed]
  91. Xu, D.; Peltz, G. Can Humanized Mice Predict Drug “Behavior” in Humans? Annu. Rev. Pharmacol. Toxicol. 2016, 56, 323–338. [Google Scholar] [CrossRef]
  92. Greener, M.J.; Roberts, R.G. Conservation of components of the dystrophin complex in Drosophila. FEBS Lett. 2000, 482, 13–18. [Google Scholar] [CrossRef]
  93. Neuman, S.; Kaban, A.; Volk, T.; Yaffe, D.; Nudel, U. The dystrophin / utrophin homologues in Drosophila and in sea urchin. Gene 2001, 263, 17–29. [Google Scholar] [CrossRef]
  94. Dekkers, L.C.; van der Plas, M.C.; van Loenen, P.B.; den Dunnen, J.T.; van Ommen, G.J.; Fradkin, L.G.; Noordermeer, J.N. Embryonic expression patterns of the Drosophila dystrophin-associated glycoprotein complex orthologs. Gene Exp. Patterns 2004, 4, 153–159. [Google Scholar] [CrossRef] [PubMed]
  95. van der Plas, M.C.; Pilgram, G.S.; Plomp, J.J.; de Jong, A.; Fradkin, L.G.; Noordermeer, J.N. Dystrophin is required for appropriate retrograde control of neurotransmitter release at the Drosophila neuromuscular junction. J. Neurosci. 2006, 26, 333–344. [Google Scholar] [CrossRef]
  96. Shcherbata, H.R.; Yatsenko, A.S.; Patterson, L.; Sood, V.D.; Nudel, U.; Yaffe, D.; Baker, D.; Ruohola-Baker, H. Dissecting muscle and neuronal disorders in a Drosophila model of muscular dystrophy. EMBO J. 2007, 26, 481–493. [Google Scholar] [CrossRef]
  97. Lin, Y.Y. Muscle diseases in the zebrafish. Neuromuscul. Disord. 2012, 22, 673–684. [Google Scholar] [CrossRef] [PubMed]
  98. Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J.E.; Humphray, S.; McLaren, K.; Matthews, L.; et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013, 496, 498–503. [Google Scholar] [CrossRef]
  99. Li, M.; Hromowyk, K.J.; Amacher, S.L.; Currie, P.D. Muscular dystrophy modeling in zebrafish. Methods Cell Biol. 2017, 138, 347–380. [Google Scholar] [CrossRef]
  100. Gibbs, E.M.; Horstick, E.J.; Dowling, J.J. Swimming into prominence: The zebrafish as a valuable tool for studying human myopathies and muscular dystrophies. FEBS J. 2013, 280, 4187–4197. [Google Scholar] [CrossRef]
  101. Goody, M.F.; Carter, E.V.; Kilroy, E.A.; Maves, L.; Henry, C.A. “Muscling” Throughout Life: Integrating Studies of Muscle Development, Homeostasis, and Disease in Zebrafish. Curr. Top. Dev. Biol. 2017, 124, 197–234. [Google Scholar] [CrossRef] [PubMed]
  102. Steffen, L.S.; Guyon, J.R.; Vogel, E.D.; Beltre, R.; Pusack, T.J.; Zhou, Y.; Zon, L.I.; Kunkel, L.M. Zebrafish orthologs of human muscular dystrophy genes. BMC Genom. 2007, 8, 79. [Google Scholar] [CrossRef] [PubMed]
  103. Widrick, J.J.; Kawahara, G.; Alexander, M.S.; Beggs, A.H.; Kunkel, L.M. Discovery of Novel Therapeutics for Muscular Dystrophies using Zebrafish Phenotypic Screens. J. Neuromuscul. Dis. 2019, 6, 271–287. [Google Scholar] [CrossRef] [PubMed]
  104. Kell, D.B. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: Where drug discovery went wrong and how to fix it. FEBS J. 2013, 280, 5957–5980. [Google Scholar] [CrossRef]
  105. Kawahara, G.; Karpf, J.A.; Myers, J.A.; Alexander, M.S.; Guyon, J.R.; Kunkel, L.M. Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 2011, 108, 5331–5336. [Google Scholar] [CrossRef]
  106. Schiavone, M.; Zulian, A.; Menazza, S.; Petronilli, V.; Argenton, F.; Merlini, L.; Sabatelli, P.; Bernardi, P. Alisporivir rescues defective mitochondrial respiration in Duchenne muscular dystrophy. Pharmacol. Res. 2017, 125, 122–131. [Google Scholar] [CrossRef]
  107. Telfer, W.R.; Busta, A.S.; Bonnemann, C.G.; Feldman, E.L.; Dowling, J.J. Zebrafish models of collagen VI-related myopathies. Hum. Mol. Genet. 2010, 19, 2433–2444. [Google Scholar] [CrossRef]
  108. Zulian, A.; Rizzo, E.; Schiavone, M.; Palma, E.; Tagliavini, F.; Blaauw, B.; Merlini, L.; Maraldi, N.M.; Sabatelli, P.; Braghetta, P.; et al. NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models. Hum. Mol. Genet. 2014, 23, 5353–5363. [Google Scholar] [CrossRef]
  109. Sileikyte, J.; Devereaux, J.; de Jong, J.; Schiavone, M.; Jones, K.; Nilsen, A.; Bernardi, P.; Forte, M.; Cohen, M.S. Second-Generation Inhibitors of the Mitochondrial Permeability Transition Pore with Improved Plasma Stability. ChemMedChem 2019, 14, 1771–1782. [Google Scholar] [CrossRef]
  110. Hirata, H.; Watanabe, T.; Hatakeyama, J.; Sprague, S.M.; Saint-Amant, L.; Nagashima, A.; Cui, W.W.; Zhou, W.; Kuwada, J.Y. Zebrafish relatively relaxed mutants have a ryanodine receptor defect, show slow swimming and provide a model of multi-minicore disease. Development 2007, 134, 2771–2781. [Google Scholar] [CrossRef]
  111. Dowling, J.J.; Arbogast, S.; Hur, J.; Nelson, D.D.; McEvoy, A.; Waugh, T.; Marty, I.; Lunardi, J.; Brooks, S.V.; Kuwada, J.Y.; et al. Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy. Brain 2012, 135, 1115–1127. [Google Scholar] [CrossRef] [PubMed]
  112. Culetto, E.; Sattelle, D.B. A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet. 2000, 9, 869–877. [Google Scholar] [CrossRef]
  113. Consortium, C.E.S. Genome sequence of the nematode C. elegans: A platform for investigating biology. Science 1998, 282, 2012–2018. [Google Scholar] [CrossRef]
  114. Ono, S. The Caenorhabditis elegans unc-78 gene encodes a homologue of actin-interacting protein 1 required for organized assembly of muscle actin filaments. J. Cell Biol. 2001, 152, 1313–1319. [Google Scholar] [CrossRef] [PubMed]
  115. Gieseler, K.; Grisoni, K.; Segalat, L. Genetic suppression of phenotypes arising from mutations in dystrophin-related genes in Caenorhabditis elegans. Curr. Biol. 2000, 10, 1092–1097. [Google Scholar] [CrossRef]
  116. Gaud, A.; Simon, J.M.; Witzel, T.; Carre-Pierrat, M.; Wermuth, C.G.; Segalat, L. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord. 2004, 14, 365–370. [Google Scholar] [CrossRef]
  117. Carre-Pierrat, M.; Mariol, M.C.; Chambonnier, L.; Laugraud, A.; Heskia, F.; Giacomotto, J.; Segalat, L. Blocking of striated muscle degeneration by serotonin in C. elegans. J. Muscle Res. Cell Motil. 2006, 27, 253–258. [Google Scholar] [CrossRef]
  118. Hwang, H.; Barnes, D.E.; Matsunaga, Y.; Benian, G.M.; Ono, S.; Lu, H. Muscle contraction phenotypic analysis enabled by optogenetics reveals functional relationships of sarcomere components in Caenorhabditis elegans. Sci. Rep. 2016, 6, 19900. [Google Scholar] [CrossRef]
  119. Virgilio, K.M.; Martin, K.S.; Peirce, S.M.; Blemker, S.S. Agent-based model illustrates the role of the microenvironment in regeneration in healthy and mdx skeletal muscle. J. Appl. Physiol. 2018, 125, 1424–1439. [Google Scholar] [CrossRef]
  120. Martin, K.S.; Blemker, S.S.; Peirce, S.M. Agent-based computational model investigates muscle-specific responses to disuse-induced atrophy. J. Appl. Physiol. 2015, 118, 1299–1309. [Google Scholar] [CrossRef]
Table 1. Key features of the various models used for neuromuscular diseases.
Table 1. Key features of the various models used for neuromuscular diseases.
Models.MyoblastsStem Cells Derived CulturesOrganoidsMuscle-on-a-ChipMouse ModelsOther Animal ModelsComputational Models
Parameter Jpm 10 00178 i001 Jpm 10 00178 i002 Jpm 10 00178 i003 Jpm 10 00178 i004 Jpm 10 00178 i005 Jpm 10 00178 i006 Jpm 10 00178 i007
Production complexityLowMedium, depends on protocolMedium/HighHigh, requires engineered chambersHighHigh/MediumMedium/High
On-platform assayEasy access to readouts, individual cell analyses possibleMedium difficulty, individual cell analyses possibleMedium/High difficulty, analyses possible at the tissue levelMedium/High, organ function analyses possibleLow difficulty, analyses possible both at cellular and tissue levelsLow difficulty, analyses possible both at cellular and tissue levelsCan account for contributions only of known variables
Duration of experimentsMinutes to daysDays to weeksDays to weeksDays to weeks, depends on platform designWeeks to monthsDays to weeksDays
Variability and clinical relevanceLow variability and relevanceHigh variability and relevanceHigh variability and relevanceLow variability, high relevanceLow variability, high relevanceLow variability, moderate relevanceLow variability but requires in vivo confirmation
Level of control over variablesHighMedium/LowLowHighHigh/MediumHigh/MediumHigh
Biodistribution and toxicology studiesUseful for initial toxicologyUseful for initial toxicologyUseful for initial toxicology and limited biodistribution studiesUseful for initial toxicology and limited biodistribution studiesUseful for toxicology, biodistribution and life span assaysUseful for toxicology and life span assaysUseful to predict outcomes
High throughput feasibilityHighMedium/HighMedium/High, depends on tissuesMedium, depends on platform designLowHighHigh
Precision medicine potentialLow, easy to manipulate but homogenous culturesHigh, takes into account individual variabilityHigh, depends on tissues and is subject to model validationHigh, allows high level of control and personalizationHigh, depends on model availabilityMedium/High, easy to manipulate but low translational relevanceHigh when used in combination with in vitro/vivo methods
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Back to TopTop